Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA3946261
Max Phase: Preclinical
Molecular Formula: C32H32Cl2N2O
Molecular Weight: 495.07
Molecule Type: Small molecule
Associated Items:
ID: ALA3946261
Max Phase: Preclinical
Molecular Formula: C32H32Cl2N2O
Molecular Weight: 495.07
Molecule Type: Small molecule
Associated Items:
Canonical SMILES: Cl.O=C(CC(c1ccccc1)c1ccccc1)N1CCN(C(c2ccccc2)c2ccc(Cl)cc2)CC1
Standard InChI: InChI=1S/C32H31ClN2O.ClH/c33-29-18-16-28(17-19-29)32(27-14-8-3-9-15-27)35-22-20-34(21-23-35)31(36)24-30(25-10-4-1-5-11-25)26-12-6-2-7-13-26;/h1-19,30,32H,20-24H2;1H
Standard InChI Key: YZINWUALFFCGMT-UHFFFAOYSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 495.07 | Molecular Weight (Monoisotopic): 494.2125 | AlogP: 6.80 | #Rotatable Bonds: 7 |
Polar Surface Area: 23.55 | Molecular Species: NEUTRAL | HBA: 2 | HBD: 0 |
#RO5 Violations: 1 | HBA (Lipinski): 3 | HBD (Lipinski): 0 | #RO5 Violations (Lipinski): 1 |
CX Acidic pKa: | CX Basic pKa: 6.36 | CX LogP: 7.08 | CX LogD: 7.04 |
Aromatic Rings: 4 | Heavy Atoms: 36 | QED Weighted: 0.28 | Np Likeness Score: -0.93 |
1. (2004) Calcium channel inhibitors comprising benzhydril spaced from piperazine, |
Source(1):